Structural Data Platform to help Advance Treatments for Brain Disease

Pharma company Lundbeck has become the first business to select Discngine’s proprietary 3decision® collaborative platform to manage its structural knowledge related to protein and ligand 3D structures. The platform, which transforms raw data coming from 3D structures and biomolecular sequences into well-organized and easily accessible knowledge, will be used by Lundbeck to help with the discovery of new treatments for brain diseases.

“We are delighted that Lundbeck has chosen our cloud platform for handling its structural knowledge. This decision shows the increasing importance of collaboration between medicinal and computational chemists,” said Eric Le Roux, founder and CEO of Discngine. “We believe that cloud computing will play an ever increasing role in pharmaceutical research, bringing significant benefits to drug developers and eventually patients.”

“It’s important for us to have instant access to all internal and external structural data, and the 3decision platform is an outstanding tool for our purposes,” said Lena Tagmose, senior director, Molecular Design and Enabling Technologies at Lundbeck. “It’s time-and cost-efficient and brings significant advantages through instant accessibility and a wide range of data modelling options.” The development of the platform began three years ago in a co-operation with Abbvie and was launched as a commercial product in 2018. This year it received the BioIT World 2019 Innovative Practices Award.